Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction

被引:58
作者
Griesinger, Georg [1 ]
Tournaye, Herman [2 ]
Macklon, Nick [3 ,4 ]
Petraglia, Felice [5 ]
Arck, Petra [6 ]
Blockeel, Christophe [2 ]
van Amsterdam, Peter [7 ]
Pexman-Fieth, Claire [8 ]
Fauser, Bart C. J. M. [9 ]
机构
[1] Univ Hosp Schleswig Holstein, Dept Gynecol Endocrinol & Reprod Med, Ratzeburger Allee 160, D-23538 Lubeck, Germany
[2] Univ Ziekenhuis Brussel, Ctr Reprod Med, Laarbeeklaan 101, B-1090 Brussels, Belgium
[3] Univ Copenhagen, Zealand Univ Hosp, Dept Obstet & Gynaecol, Alleen 15, DK-4180 Roskilde, Denmark
[4] London Womens Clin, 113-115 Harley St, London W1G 6AP, England
[5] Univ Florence, Dept Biomed Expt & Clin Sci, Obstet & Gynecol, Piazzale Brambilla 3, I-50134 Florence, Italy
[6] Univ Med Ctr Hamburg Eppendorf, Dept Obstet & Fetal Med, Martinistr 52, D-20246 Hamburg, Germany
[7] Abbott Healthcare Prod BV, CJ van Houtenlaan 36, NL-1381 CP Weesp, Netherlands
[8] Abbott GmbH & Co KG, Max Planck Ring 2, D-65205 Wiesbaden, Germany
[9] Univ Med Ctr Utrecht, Dept Reprod Med & Gynecol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
关键词
Duphaston; Dydrogesterone; In-vitro fertilization; Luteal phase support; Pharmacological profile; Progesterone; IN-VITRO FERTILIZATION; MICRONIZED VAGINAL PROGESTERONE; FOLLICLE-STIMULATING-HORMONE; CONGENITAL HEART-DISEASE; NITRIC-OXIDE SYNTHESIS; ORAL DYDROGESTERONE; LUTEINIZING-HORMONE; OVARIAN STIMULATION; EARLY-PREGNANCY; INTRAMUSCULAR PROGESTERONE;
D O I
10.1016/j.rbmo.2018.11.017
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The pharmacological and physiological profiles of progestogens used for luteal phase support during assisted reproductive technology are likely to be important in guiding clinical choice towards the most appropriate treatment option. Various micronized progesterone formulations with differing pharmacological profiles have been investigated for several purposes. Dydrogesterone, a stereoisomer of progesterone, is available in an oral form with high oral bioavailability; it has been used to treat a variety of conditions related to progesterone deficiency since the 1960s and has recently been approved for luteal phase support as part of an assisted reproductive technology treatment. The primary objective of this review is to critically analyse the clinical implications of the pharmacological and physiological properties of dydrogesterone for its uses in luteal phase support and in early pregnancy.
引用
收藏
页码:249 / 259
页数:11
相关论文
共 112 条
[1]  
Abbott B. V., 2017, DUPHASTON 10 FILM CO
[2]   Determination of dydrogesterone in human plasma by tandem mass spectrometry: Application to therapeutic drug monitoring of dydrogesterone in gynecological disorders [J].
Abdel-Hamid, M. E. ;
Sharaf, L. H. ;
Kombian, S. B. ;
Diejomaoh, F. M. E. .
CHROMATOGRAPHIA, 2006, 64 (5-6) :287-292
[3]  
Abdel-Razik Mohamed, 2014, J Reprod Infertil, V15, P142
[4]  
Al Jasem Y., 2014, Mediterr. J. Chem, V3, P796, DOI [10.13171/mjc.3.2.2014.18.04.15, DOI 10.13171/MJC.3.2.2014.18.04.15]
[5]   Fetomaternal immune cross-talk and its consequences for maternal and offspring's health [J].
Arck, Petra C. ;
Hecher, Kurt .
NATURE MEDICINE, 2013, 19 (05) :548-556
[6]   Membrane progesterone receptors in human regulatory T cells: a reality in pregnancy [J].
Areia, A. ;
Vale-Pereira, S. ;
Alves, V. ;
Rodrigues-Santos, P. ;
Moura, P. ;
Mota-Pinto, A. .
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2015, 122 (11) :1544-1550
[7]   Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone [J].
Arvidsson, C ;
Hellborg, M ;
Gemzell-Danielsson, K .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2005, 123 (01) :87-91
[8]  
AYDAR CK, 1964, INT J FERTIL, V9, P585
[9]  
BACKER MH, 1962, OBSTET GYNECOL, V19, P724
[10]   Intrahepatic cholestasis of pregnancy: A French prospective study [J].
Bacq, Y ;
Sapey, T ;
Brechot, MC ;
Pierre, F ;
Fignon, A ;
Dubois, F .
HEPATOLOGY, 1997, 26 (02) :358-364